# Clinical Trials Data EGFR - Document 147

# The Oncopanel Pilot (TOP) Study

## Clinical Trial: https://clinicaltrials.gov/study/NCT02171286

"eligibilityCriteria": "Patients with archival tumor tissue and a known history of invasive malignancies are eligible if they meet one or more of the following criteria:\n\n\* Advanced colorectal cancer and eligible for standard KRAS testing,\n\* Advanced non-small cell lung cancer and eligible for standard EGFR testing,\n\* Advanced melanoma and eligible for standard BRAF testing,\n\* Gastrointestinal stromal tumors (GISTs) eligible for standard c-KIT and PDGFRA testing,\n\* Being considered for potential eligibility in clinical trial.",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "Patients with advanced colorectal cancer, non-small cell lung cancer and melanoma and candidates for clinical trials.",

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
Based on the provided eligibility criteria, a patient with an EGFR gene mutation would be potentially eligible for this clinical trial if they have advanced non-small cell lung cancer (NSCLC) and are eligible for standard EGFR testing. The criteria specify that patients with advanced NSCLC and qualified for EGFR testing are eligible, which directly includes those with an EGFR mutation within this specific cancer type.